Area of research
Cancer Research · Oncology
Research interest
Research focused on Pembrolizumab and Immune system, with related work in Pancreatic cancer, Cancer research, Chimeric antigen receptor. Notable publications include 'Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy', 'Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity', and 'Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies'.
Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity
A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy.